BPG is committed to discovery and dissemination of knowledge
Observational Study
©The Author(s) 2025.
World J Hepatol. Oct 27, 2025; 17(10): 109583
Published online Oct 27, 2025. doi: 10.4254/wjh.v17.i10.109583
Table 3 Treatment rates and disease-related variables before and after the educational video module, n (%)
TreatmentGroup
P value
Pre-intervention (n = 43)
Post-intervention (n = 43)
Pharmacy treatment0.021
No31 (72.1)22 (51.2)
Yes12 (27.9)21 (48.8)
Missing00
Acamprosate0.481
No40 (93.0)38 (88.4)
Yes3 (7.0)5 (11.6)
Missing00
Disulfiram
No43 (100)43 (100)-
Missing00-
Naltrexone0.201
No34 (79.1)29 (67.4)
Yes9 (20.9)14 (32.6)
Missing00
Vivitrol0.171
No34 (79.1)29 (67.4)
Yes9 (20.9)14 (32.6)
Missing00
Behavioral treatment0.0031
No27 (62.8)12 (27.9)
Yes16 (37.2)31 (72.1)
Missing00
Inpatient treatment0.261
No36 (83.7)39 (90.7)
Yes7 (16.3)4 (9.3)
Missing00
Outpatient treatment0.00021
No39 (90.7)23 (53.5)
Yes4 (9.3)20 (46.5)
Missing00
Mutual aid0.101
No28 (66.7)20 (47.6)
Yes14 (33.3)22 (52.4)
Missing11
Behavioral and pharmacologictreatment0.0071
No37 (88.1)25 (59.5)
Yes5 (11.9)17 (40.5)
Missing11


Write to the Help Desk